Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MAP3K1

From Wikipedia, the free encyclopedia
Protein-coding gene in the species Homo sapiens
MAP3K1
Identifiers
AliasesMAP3K1, MAPKKK1, MEKK, MEKK 1, MEKK1, SRXY6, mitogen-activated protein kinase kinase kinase 1
External IDsOMIM:600982;MGI:1346872;HomoloGene:8056;GeneCards:MAP3K1;OMA:MAP3K1 - orthologs
Gene location (Human)
Chromosome 5 (human)
Chr.Chromosome 5 (human)[1]
Chromosome 5 (human)
Genomic location for MAP3K1
Genomic location for MAP3K1
Band5q11.2Start56,815,549bp[1]
End56,896,152bp[1]
Gene location (Mouse)
Chromosome 13 (mouse)
Chr.Chromosome 13 (mouse)[2]
Chromosome 13 (mouse)
Genomic location for MAP3K1
Genomic location for MAP3K1
Band13 D2.2|13 63.36 cMStart111,882,962bp[2]
End111,945,527bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • buccal mucosa cell

  • skin of thigh

  • skin of hip

  • parotid gland

  • corpus epididymis

  • monocyte

  • vulva

  • oral cavity

  • lactiferous duct

  • gums
Top expressed in
  • corneal stroma

  • submandibular gland

  • lactiferous gland

  • parotid gland

  • cumulus cell

  • blood

  • epithelium of stomach

  • neural layer of retina

  • Ileal epithelium

  • spleen
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo /QuickGO
Orthologs
SpeciesHumanMouse
Entrez

4214

26401

Ensembl

ENSG00000095015

ENSMUSG00000021754

UniProt

Q13233

P53349

RefSeq (mRNA)

NM_005921

NM_011945

RefSeq (protein)

NP_005912

n/a

Location (UCSC)Chr 5: 56.82 – 56.9 MbChr 13: 111.88 – 111.95 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) is asignal transductionenzyme that in humans is encoded by theautosomalMAP3K1gene.[5][6]

Function

[edit]

MAP3K1 (or MEKK1) is a serine/threoninekinase andubiquitin ligase that performs a pivotal role in a network ofenzymes integrating cellular receptor responses to a number of mitogenic and metabolic stimuli, including:TNF receptor superfamily (TNFRs),T-cell receptor (TCR),Epidermal growth factor receptor (EGFR), andTGF beta receptor (TGFβR).[7][8]Mitogen-activated protein kinase kinases (MAP2Ks) are substrates for direct phosphorylation by the MAP3K1protein kinase.[9][10] The MAP3K1 kinase domain may also be a modest activator of IκB kinase activation.[11] The MAP3K1 E3 ubiquitin ligase recruits aubiquitin-conjugating enzyme (includingUBE2D2,UBE2D3, andUBE2N:UBE2V1) that has been loaded withubiquitin, interacts with its substrates, and facilitates the transfer of ubiquitin from the ubiquitin-conjugating enzyme onto its substrates.[12] Genetics has revealed thatMAP3K1 is important in:embryonic development,tumorigenesis,cell growth,cell migration,cytokine production, andhumoral immunity.[8]MAP3K1 mutants were identified inbreast cancer byGWAS.[13][14]

Structure

[edit]

MAP3K1 contains aprotein kinase domain,PHD finger (which has aRING finger domain-like structure) that serves as anE3 ubiquitin ligase, andscaffold protein regions that mediateprotein–protein interactions.[15][16][17][18]

Genetic analyses in murine and avian models

[edit]

MAP3K1 is highly conserved inEuteleostomi.[19] The spontaneousrecessive lidgap-Gates mutation (deletion ofMap3k1 exons 2–9, initially described in the 1960s) identified on the SELH/Bc mouse strain causes the same open-eyelids-at-birth mutational phenotype as the gene knockout mutations of the mouse (but not human)MAP3K1homolog (Map3k1) and also co-maps to distal Chromosome 13.[20]MAP3K1 was analysed genetically by targeted mutagenesis usingtransgenic mice (C57BL/6 and C57BL/6 × 129 backgrounds),embryonic stem cells, and the DT40cell line to identifygenetic traits.

Map3k1 mutantSpeciesGenetic modelReferences
Deletion of 132 codons inMap3k1 exon 1Mus musculusTransgenic mouse and embryonic stem cells[21][22][23][24]
Deletion kinase domainMus musculusTransgenic mouse and embryonic stem cells[25][26][27][28][29]
Point mutations inMap3k1 exon 7 encoding E3 ubiquitin ligaseMus musculusTransgenic mouse and embryonic stem cells[12]
T cell-specific deletion generated byLck promoter-drivenCreMus musculusTransgenic mouse[30]
Deletioncarboxyl-terminusGallus gallus domesticusLymphoblast cell line[31][32]

Mechanism of MAPK activation by MAP3K1

[edit]

MAP3K1 contains multipleamino acid sites that arephosphorylated andubiquitinated.[33] Early biochemical analysis demonstrated that triple co-expression of MAP3K1, MAP2K and MAPK in bacterial cells was sufficient for the activation of MAPK.[34] Later analysis ofsyngenic mice that harbour mutations inTRAF2,UBE2N,Map3k1 andMap3k7 identified critical regulators of cytokine-inducedMAPK signal transduction in B cells.[35][36][37][38]Cytokine signaling through MAP3K1 utilises two-stagecell signaling to recruit thesignal transduction mechanism tocytokine receptors and then release the signal transduction components, altered bypost-translational modification, from thecellular membrane to activate MAPKs.[39][40]Genetic analysis has demonstrated that the E3 Ub ligase  and the kinase domains of MAP3K1 are required forMAPK activation.[32][41][42]

MAP3K1 signal transduction.A. Cytokine receptor prior to ligation by cytokine.B. Recruitment of TRAFs 2, 3 and 6 to the cytokine receptor.C. Ubiquitination of TRAFs. Recruitment of MAP3K1 and MAP3K7 signaling modules to TRAFs and scaffolding.D. Degradation of canonical Ubiquitin-TRAF3 by the proteasome, release of non-canonical Ubiquitin-TRAF2 and -MAP3Ks into the cytoplasm, and activation of MAP2K signaling.

Cancers, other diseases and therapeutic targeting

[edit]

MAP3K1 is abiomarker mutated in 3.24% of all human cancers.[43]MAP3K1 has been associated with several diseases in non-syngeneic human populations,[44] including:breast cancer,[45]adenocarcinoma of theprostate,[46] sarcomatoidhepatocellular carcinoma,[47]acute respiratory distress syndrome,[48]Langerhans cell histiocytosis,[49] and 46,XYdisorders of sex development.[50] E6201 is anenzyme inhibitor of MAP3K1 that shows cross-specificity withMAP2K1.[51]

Interaction partners

[edit]

MAP3K1 has been shown tointeract with a number of proteins,[44] including:

References

[edit]
  1. ^abcGRCh38: Ensembl release 89: ENSG00000095015Ensembl, May 2017
  2. ^abcGRCm38: Ensembl release 89: ENSMUSG00000021754Ensembl, May 2017
  3. ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^Vinik BS, Kay ES, Fiedorek FT (November 1995). "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and human chromosome 5".Mammalian Genome.6 (11):782–783.doi:10.1007/BF00539003.PMID 8597633.S2CID 37828255.
  6. ^"Entrez Gene: MAP3K1 mitogen-activated protein kinase kinase kinase 1".
  7. ^Schlesinger TK, Fanger GR, Yujiri T, Johnson GL (November 1998). "The TAO of MEKK".Frontiers in Bioscience.3 (4):D1181 –D1186.doi:10.2741/a354.PMID 9820741.
  8. ^abSuddason T, Gallagher E (April 2015)."A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1".Cell Death and Differentiation.22 (4):540–548.doi:10.1038/cdd.2014.239.PMC 4356348.PMID 25613373.
  9. ^Minden A, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, et al. (December 1994). "Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK".Science.266 (5191):1719–1723.Bibcode:1994Sci...266.1719M.doi:10.1126/science.7992057.PMID 7992057.
  10. ^Karin M, Gallagher E (2005). "From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance".IUBMB Life.57 (4–5):283–295.doi:10.1080/15216540500097111.PMID 16036612.S2CID 25508987.
  11. ^Karin M, Delhase M (August 1998)."JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?".Proceedings of the National Academy of Sciences of the United States of America.95 (16):9067–9069.Bibcode:1998PNAS...95.9067K.doi:10.1073/pnas.95.16.9067.PMC 33875.PMID 9689033.
  12. ^abCharlaftis N, Suddason T, Wu X, Anwar S, Karin M, Gallagher E (November 2014)."The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines".The EMBO Journal.33 (21):2581–2596.doi:10.15252/embj.201488351.PMC 4282369.PMID 25260751.
  13. ^Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, et al. (January 2015)."Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1".American Journal of Human Genetics.96 (1):5–20.doi:10.1016/j.ajhg.2014.11.009.PMC 4289692.PMID 25529635.
  14. ^Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. (June 2007)."Genome-wide association study identifies novel breast cancer susceptibility loci".Nature.447 (7148):1087–1093.Bibcode:2007Natur.447.1087E.doi:10.1038/nature05887.PMC 2714974.PMID 17529967.
  15. ^"Q13233 (M3K1_HUMAN)".Swiss Model. Swiss Institute of Bioinformatics.
  16. ^Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ (22–29 December 1994). "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1".Nature.372 (6508):798–800.Bibcode:1994Natur.372..798Y.doi:10.1038/372798a0.PMID 7997270.S2CID 4369739.
  17. ^Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T (May 2002)."The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2".Molecular Cell.9 (5):945–956.doi:10.1016/s1097-2765(02)00519-1.PMID 12049732.
  18. ^Filipčík P, Latham SL, Cadell AL, Day CL, Croucher DR, Mace PD (September 2020)."A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomers".Proceedings of the National Academy of Sciences of the United States of America.117 (35):21308–21318.Bibcode:2020PNAS..11721308F.doi:10.1073/pnas.2006429117.PMC 7474687.PMID 32817551.
  19. ^"HomoloGene - NCBI".www.ncbi.nlm.nih.gov. Archived fromthe original on April 30, 2025. Retrieved2020-05-01.
  20. ^Juriloff DM, Harris MJ, Mah DG (January 2005). "The open-eyelid mutation, lidgap-Gates, is an eight-exon deletion in the mouse Map3k1 gene".Genomics.85 (1):139–142.doi:10.1016/j.ygeno.2004.10.002.PMID 15607429.
  21. ^Yujiri T, Sather S, Fanger GR, Johnson GL (December 1998). "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption".Science.282 (5395):1911–1914.Bibcode:1998Sci...282.1911Y.doi:10.1126/science.282.5395.1911.PMID 9836645.
  22. ^Yujiri T, Ware M, Widmann C, Oyer R, Russell D, Chan E, et al. (June 2000)."MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation".Proceedings of the National Academy of Sciences of the United States of America.97 (13):7272–7277.Bibcode:2000PNAS...97.7272Y.doi:10.1073/pnas.130176697.PMC 16535.PMID 10852963.
  23. ^Yujiri T, Fanger GR, Garrington TP, Schlesinger TK, Gibson S, Johnson GL (April 1999)."MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton".The Journal of Biological Chemistry.274 (18):12605–12610.doi:10.1074/jbc.274.18.12605.PMID 10212239.S2CID 37158636.
  24. ^Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N (December 1999)."MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes".Proceedings of the National Academy of Sciences of the United States of America.96 (26):15127–15132.Bibcode:1999PNAS...9615127M.doi:10.1073/pnas.96.26.15127.PMC 24784.PMID 10611349.
  25. ^Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, et al. (September 2003)."A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure".The EMBO Journal.22 (17):4443–4454.doi:10.1093/emboj/cdg440.PMC 202382.PMID 12941696.
  26. ^Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, Karin M (October 2004)."Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch".Science.306 (5694):271–275.Bibcode:2004Sci...306..271G.doi:10.1126/science.1099414.PMID 15358865.S2CID 31876966.
  27. ^Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D, Holzer R, et al. (January 2007). "Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production".Nature Immunology.8 (1):57–63.doi:10.1038/ni1421.PMID 17143273.S2CID 23344995.
  28. ^Bonnesen B, Orskov C, Rasmussen S, Holst PJ, Christensen JP, Eriksen KW, et al. (November 2005)."MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver".Blood.106 (10):3396–3404.doi:10.1182/blood-2005-04-1739.PMID 16081685.S2CID 19307521.
  29. ^Labuda T, Christensen JP, Rasmussen S, Bonnesen B, Karin M, Thomsen AR, Odum N (August 2006)."MEK kinase 1 is a negative regulator of virus-specific CD8(+) T cells".European Journal of Immunology.36 (8):2076–2084.doi:10.1002/eji.200535163.PMID 16761309.S2CID 12332084.
  30. ^Suddason T, Anwar S, Charlaftis N, Gallagher E (January 2016)."T-Cell-Specific Deletion of Map3k1 Reveals the Critical Role for Mekk1 and Jnks in Cdkn1b-Dependent Proliferative Expansion".Cell Reports.14 (3):449–457.doi:10.1016/j.celrep.2015.12.047.PMC 4733086.PMID 26774476.
  31. ^Kwan R, Burnside J, Kurosaki T, Cheng G (November 2001)."MEKK1 is essential for DT40 cell apoptosis in response to microtubule disruption".Molecular and Cellular Biology.21 (21):7183–7190.doi:10.1128/MCB.21.21.7183-7190.2001.PMC 99893.PMID 11585901.
  32. ^abTricker E, Arvand A, Kwan R, Chen GY, Gallagher E, Cheng G (February 2011)."Apoptosis induced by cytoskeletal disruption requires distinct domains of MEKK1".PLOS ONE.6 (2) e17310.Bibcode:2011PLoSO...617310T.doi:10.1371/journal.pone.0017310.PMC 3045432.PMID 21364884.
  33. ^"MEKK1 (human)".www.phosphosite.org. Retrieved2020-02-26.
  34. ^Khokhlatchev A, Xu S, English J, Wu P, Schaefer E, Cobb MH (April 1997)."Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases".The Journal of Biological Chemistry.272 (17):11057–11062.doi:10.1074/jbc.272.17.11057.PMID 9110999.
  35. ^Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y (November 1997)."TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival".Immunity.7 (5):703–713.doi:10.1016/s1074-7613(00)80390-8.PMID 9390693.
  36. ^Yamamoto M, Okamoto T, Takeda K, Sato S, Sanjo H, Uematsu S, et al. (September 2006). "Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling".Nature Immunology.7 (9):962–970.doi:10.1038/ni1367.PMID 16862162.S2CID 34181754.
  37. ^Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. (November 2005). "Essential function for the kinase TAK1 in innate and adaptive immune responses".Nature Immunology.6 (11):1087–1095.doi:10.1038/ni1255.PMID 16186825.S2CID 13005309.
  38. ^Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D, Holzer R, et al. (January 2007). "Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production".Nature Immunology.8 (1):57–63.doi:10.1038/ni1421.PMID 17143273.S2CID 23344995.
  39. ^Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al. (August 2008)."Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex".Science.321 (5889):663–668.Bibcode:2008Sci...321..663M.doi:10.1126/science.1157340.PMC 2669719.PMID 18635759.
  40. ^Karin M, Gallagher E (March 2009). "TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes".Immunological Reviews.228 (1):225–240.doi:10.1111/j.1600-065X.2008.00755.x.PMID 19290931.S2CID 1683105.
  41. ^abCharlaftis N, Suddason T, Wu X, Anwar S, Karin M, Gallagher E (November 2014)."The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines".The EMBO Journal.33 (21):2581–2596.doi:10.15252/embj.201488351.PMC 4282369.PMID 25260751.
  42. ^Xia Y, Makris C, Su B, Li E, Yang J, Nemerow GR, Karin M (May 2000)."MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration".Proceedings of the National Academy of Sciences of the United States of America.97 (10):5243–5248.Bibcode:2000PNAS...97.5243X.doi:10.1073/pnas.97.10.5243.PMC 25813.PMID 10805784.
  43. ^"MAP3K1 - My Cancer Genome".www.mycancergenome.org. Retrieved2020-02-26.
  44. ^ab"MAP3K1 mitogen-activated protein kinase kinase kinase 1 [Homo sapiens (human)] - Gene - NCBI".www.ncbi.nlm.nih.gov. Retrieved2020-05-02.
  45. ^Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. (May 2012)."The landscape of cancer genes and mutational processes in breast cancer".Nature.486 (7403):400–404.Bibcode:2012Natur.486..400..doi:10.1038/nature11017.PMC 3428862.PMID 22722201.
  46. ^Shojo K, Kosaka T, Nakamura K, Hongo H, Kobayashi H, Mikami S, et al. (May 2021)."First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion".IJU Case Reports.4 (3):176–179.doi:10.1002/iju5.12274.PMC 8088887.PMID 33977253.
  47. ^Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang X, et al. (September 2021)."Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome".Cancer Medicine.10 (18):6227–6238.doi:10.1002/cam4.4162.PMC 8446410.PMID 34331411.
  48. ^Morrell ED, O'Mahony DS, Glavan BJ, Harju-Baker S, Nguyen C, Gunderson S, et al. (January 2018)."Genetic Variation in MAP3K1 Associates with Ventilator-Free Days in Acute Respiratory Distress Syndrome".American Journal of Respiratory Cell and Molecular Biology.58 (1):117–125.doi:10.1165/rcmb.2017-0030OC.PMC 5941309.PMID 28858533.
  49. ^Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, et al. (June 2015)."MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis".Genes, Chromosomes & Cancer.54 (6):361–368.doi:10.1002/gcc.22247.PMID 25899310.S2CID 6264217.
  50. ^Pearlman A, Loke J, Le Caignec C, White S, Chin L, Friedman A, et al. (December 2010)."Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination".American Journal of Human Genetics.87 (6):898–904.doi:10.1016/j.ajhg.2010.11.003.PMC 2997363.PMID 21129722.
  51. ^Goto M, Chow J, Muramoto K, Chiba K, Yamamoto S, Fujita M, et al. (November 2009). "E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities".The Journal of Pharmacology and Experimental Therapeutics.331 (2):485–495.doi:10.1124/jpet.109.156554.PMID 19684251.S2CID 37755563.
  52. ^Zhang Y, Qiu WJ, Chan SC, Han J, He X, Lin SC (May 2002)."Casein kinase I and casein kinase II differentially regulate axin function in Wnt and JNK pathways".The Journal of Biological Chemistry.277 (20):17706–17712.doi:10.1074/jbc.M111982200.PMID 11884395.
  53. ^Zhang Y, Neo SY, Han J, Lin SC (August 2000)."Dimerization choices control the ability of axin and dishevelled to activate c-Jun N-terminal kinase/stress-activated protein kinase".The Journal of Biological Chemistry.275 (32):25008–25014.doi:10.1074/jbc.M002491200.PMID 10829020.
  54. ^Karandikar M, Xu S, Cobb MH (December 2000)."MEKK1 binds raf-1 and the ERK2 cascade components".The Journal of Biological Chemistry.275 (51):40120–40127.doi:10.1074/jbc.M005926200.PMID 10969079.
  55. ^Pomérance M, Multon MC, Parker F, Venot C, Blondeau JP, Tocqué B, Schweighoffer F (September 1998)."Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor".The Journal of Biological Chemistry.273 (38):24301–24304.doi:10.1074/jbc.273.38.24301.PMID 9733714.
  56. ^Xu S, Cobb MH (December 1997)."MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases".The Journal of Biological Chemistry.272 (51):32056–32060.doi:10.1074/jbc.272.51.32056.PMID 9405400.
  57. ^Baud V, Liu ZG, Bennett B, Suzuki N, Xia Y, Karin M (May 1999)."Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain".Genes & Development.13 (10):1297–1308.doi:10.1101/gad.13.10.1297.PMC 316725.PMID 10346818.
  58. ^Saltzman A, Searfoss G, Marcireau C, Stone M, Ressner R, Munro R, et al. (April 1998)."hUBC9 associates with MEKK1 and type I TNF-alpha receptor and stimulates NFkappaB activity".FEBS Letters.425 (3):431–435.Bibcode:1998FEBSL.425..431S.doi:10.1016/s0014-5793(98)00287-7.PMID 9563508.S2CID 84816080.
  59. ^Gallagher ED, Gutowski S, Sternweis PC, Cobb MH (January 2004)."RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity".The Journal of Biological Chemistry.279 (3):1872–1877.doi:10.1074/jbc.M309525200.PMID 14581471.
  60. ^Fanger GR, Johnson NL, Johnson GL (August 1997)."MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42".The EMBO Journal.16 (16):4961–4972.doi:10.1093/emboj/16.16.4961.PMC 1170131.PMID 9305638.
  61. ^Christerson LB, Gallagher E, Vanderbilt CA, Whitehurst AW, Wells C, Kazempour R, et al. (August 2002). "p115 Rho GTPase activating protein interacts with MEKK1".Journal of Cellular Physiology.192 (2):200–208.doi:10.1002/jcp.10125.PMID 12115726.S2CID 33717402.
  62. ^Xia Y, Wu Z, Su B, Murray B, Karin M (November 1998)."JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension".Genes & Development.12 (21):3369–3381.doi:10.1101/gad.12.21.3369.PMC 317229.PMID 9808624.
  63. ^Yujiri T, Nawata R, Takahashi T, Sato Y, Tanizawa Y, Kitamura T, Oka Y (February 2003)."MEK kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression".The Journal of Biological Chemistry.278 (6):3846–3851.doi:10.1074/jbc.M206087200.PMID 12458213.

Further reading

[edit]
  • Lin, A (2006). "The JNK Signaling Pathway (Molecular Biology Intelligence Unit)".Landes Bioscience.1:1–97.ISBN 978-1-58706-120-2.
Non-specific serine/threonine protein kinases (EC 2.7.11.1)
Pyruvate dehydrogenase kinase (EC 2.7.11.2)
Dephospho-(reductase kinase) kinase (EC 2.7.11.3)
3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring) kinase (EC 2.7.11.4)
(isocitrate dehydrogenase (NADP+)) kinase (EC 2.7.11.5)
(tyrosine 3-monooxygenase) kinase (EC 2.7.11.6)
Myosin-heavy-chain kinase (EC 2.7.11.7)
Fas-activated serine/threonine kinase (EC 2.7.11.8)
Goodpasture-antigen-binding protein kinase (EC 2.7.11.9)
  • -
IκB kinase (EC 2.7.11.10)
cAMP-dependent protein kinase (EC 2.7.11.11)
cGMP-dependent protein kinase (EC 2.7.11.12)
Protein kinase C (EC 2.7.11.13)
Rhodopsin kinase (EC 2.7.11.14)
Beta adrenergic receptor kinase (EC 2.7.11.15)
G-protein coupled receptor kinases (EC 2.7.11.16)
Ca2+/calmodulin-dependent (EC 2.7.11.17)
Myosin light-chain kinase (EC 2.7.11.18)
Phosphorylase kinase (EC 2.7.11.19)
Elongation factor 2 kinase (EC 2.7.11.20)
Polo kinase (EC 2.7.11.21)
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
Polo kinase (EC 2.7.11.21)
Cyclin-dependent kinase (EC 2.7.11.22)
(RNA-polymerase)-subunit kinase (EC 2.7.11.23)
Mitogen-activated protein kinase (EC 2.7.11.24)
MAP3K (EC 2.7.11.25)
Tau-protein kinase (EC 2.7.11.26)
(acetyl-CoA carboxylase) kinase (EC 2.7.11.27)
  • -
Tropomyosin kinase (EC 2.7.11.28)
  • -
Low-density-lipoprotein receptor kinase (EC 2.7.11.29)
  • -
Receptor protein serine/threonine kinase (EC 2.7.11.30)
MAP2K
Activity
Regulation
Classification
Kinetics
Types
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=MAP3K1&oldid=1314083770"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp